Compugen's Out-Licensed Lung Cancer Candidate Enters Human Trial

Comments
Loading...
  • AstraZeneca Plc's AZN bispecific antibody derived from Compugen Ltd's CGEN COM902 will advance into clinical development
  • AstraZeneca plans to initiate a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer.
  • COM902 was licensed to AstraZeneca in 2018 exclusively to develop bispecific and multi-specific antibody products, with AstraZeneca responsible for all research, development, and commercial activities. 
  • Compugen retains all other rights to the program, except those licensed to AstraZeneca.
  • Price Action: CGEN shares are down 1.51% at $5.89, and AZN stock is up 0.42% at $59.69 during the market session on the last check Thursday.
AZN Logo
AZNAstraZeneca PLC
$77.481.27%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum73.21
Growth43.80
Quality58.82
Value18.57
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: